We presented continued positive data from our Phase II ADVANCE II trial in MRD+ AML at ASH, the American Society of Hematology conference, and last year's updated Clinical Development Strategy in Acute Myeloid Leukemia (AML) aligns with the evolution of first-line treatment, which we will also discuss, specifically how that first-line treatment is shaping up, including recent updates that took place at the ASH conference last December. Let me move to the data we presented at ASH.
You are familiar with this picture. We have, of course, provided continued updates on the long-term survival of the patients that participated in the ADVANCE II Phase 2 trial.
These were all patients that had undergone high intensity chemotherapy after being diagnosed with acute myeloid leukemia and were diagnosed with measurable residual disease, which is a high risk factor in predicting the probability of relapse and ultimately overall survival. The positive news is that the patients are still doing very well. The patients in long-term follow-up continue to do well. Eight patients have now passed five-year survival, and we have not yet reached median overall or relapse-free survival if we look at the projected five-year survival of 63%. That compares to historical controls, including, for example, the registration trial with oral Azacitidine, which is now an approved drug in this setting in acute myeloid leukemia of less than 30%. So this not only, let's say, in terms of numbers, but also particularly what you call a plateau, so that you see that you really have a patient population that is stable over a longer period of time, is indicative of the active immunotherapy effect that we, of course, aim to introduce to the benefit of patients.
And the data also, combined with the general very benign safety profile of the product, will allow us to establish a very broad positioning of vididencel as post-remission therapy across different AML subtypes. The last remark about immunotherapy versus targeted therapies, which are typically directed towards specific mutations, both in the phase one trial and in the phase two trial. We have seen no association between the outcome of the treatment and specific mutations, which means that we can also position this product independently of particular mutations in AML, and that makes it, alongside its safety profile, highly competitive in this indication.
Now, what was the update at ASH that was relevant in the evolution of first-line treatment in AML? The patients that are representing roughly half of the patient population in AML, which are either elderly patients above 75 years of age or that have other risk factors that make them a patient population which is described as unfit for intensive chemotherapy. Until recently, these patients had a very poor prognosis and a very poor probability of even accomplishing complete remissions. That has changed dramatically with the development of a new drug called Venetoclax, which is in clinical practice combined with injectable Azacitidine, and that combination is called Ven+Aza, sometimes also referred to as Aza+Ven, but it's always a combination of oral Venetoclax combined with injectable Azacitidine. What was interesting is that, in the paradigm trial, which was presented at ASH, this is a large trial with fit patients.
So patients that in principle could undergo high intensity chemotherapy. But here they were randomized to either high-intensity chemotherapy or Ven+Aza. The outcome of that trial, and this is a Phase 2 trial, was that the fit patients actually benefited from being treated with Ven+Aza versus high intensity chemotherapy.
There was, certainly in the first year, a significant difference between event-free survival that was better in the Aza-treated group as compared to high-intensity chemotherapy.
And also there were less severe side effects, less hospitalizations, less ICU usage, and less infection. So this means that there will be a continued drive to position Venetoclax as a first-line treatment in AML, beyond the patient population that was traditionally classified as unfit. And of course, it's important for us as a post-remission treatment that we anticipate the evolution of the field, including the broader use of Venetoclax driven by its clinical success. So what we are currently doing is the ADVANCE II trial was a single-agent trial, and we had already started the CADENCE phase two trial, which is a randomized trial in which we combine vididencel with oral azacitidine following high-intensity chemotherapy. But we will now also engage in the DIVA phase one B trial, which we are preparing with Andrew Wei, who is also the principal investigator of the CADENCE trial. Professor Wei has been very influential, particularly in the development of Venetoclax. And what we will do is in the phase one trial, combine Vididencel with Venetoclax and Azacitidine as a first line treatment. And this will allow us to much more broadly position vididencel as an immunotherapy in AML.
Then chronic myeloid leukemia as an indication that we had considered over a longer period of time. But the development of our clinical development strategy accelerated significantly when Tariq Mughal joined us as Chief Medical Officer mid-last year in 2025. Tariq has a long background in chronic myeloid leukemia, and he has helped us basically put in place the strategy, which will allow us to test Vididencel as an immunotherapy in CML. Now, what's the relevance of this strategy in CML?
Chronic myeloid leukemia, as the name says, is a chronic indication. In the past, CML was treated with hematopoietic stem cell transplants or bone marrow transplants, similar to AML. But in the past decades, after the discovery of so-called tyrosine kinase inhibitors that are suppressing the BCR-ABL1 oncogene, which is a specific driver mutation of CML, the disease is more or less under control as long as patients keep on taking the TKIs. So we are seeing a fast-growing patient population because of the chronic nature of the disease.
We are now already talking about roughly 300,000 patients in Europe and the US alone.
And all these patients have to take TKIs on a daily basis.
On the one hand, the overall survival of CML patients is now close to that of the general population. But on the other hand, you can imagine it's a huge burden. They have to take their tyrosine kinase inhibitors treatment for the rest of their lives. So from an immediate disease control question, the treatment of CML has shifted to a quality of life question. And of course, with all the costs associated with treatment, there would also be a significant reduction in costs if we were able to allow more patients to stop their TKI treatment.
So this new barrier in the treatment of CML is called treatment-free remission, or TFR. And it has become a key therapy goal. The problem is, as soon as you stop treating patients with TKIs, the disease comes back. And that's called a molecular relapse. And it's also called TFR failure. So patients have to then be put on either their original TKI or a next generation TKI.
There has been an evolution in the development of TKIs, and this continues into the next generation. TKIs are already being developed. There are large companies, first of all, Novartis. But then also in the US, companies like Terns and Enliven that are developing more effective and more specific TKIs. But the next wave of innovation will come from compounds that will allow patients to have a more successful TFR attempt. And this is where we believe immunotherapy can play a significant role. If the immune system is able to control the residual disease, the probability of a successful TFR attempt will be higher. Now this hypothesis, we will first test in the VITAL-CML phase one trial, which we are currently preparing, and we hope to start this trial in the second quarter of this year, subject to timely regulatory approval of the trial. We have filed for all regulatory approvals. But of course, now we have to wait for that approval to start the trial.
The recruitment in CML, we expect, will be a lot quicker than in AML because of the larger number of patients and also the patients already having been pre-screened to take part in this trial. So, in that sense, we can also quite accurately predict that we will have initial data from the Phase 1 trial confirming the safety of vididencel in this indication. And then in parallel, we will start a Phase 2a trial, which is called the VITAL-TFR2 trial. And that trial will specifically focus on patients that will attempt to achieve treatment-free remission, but they will do that after they had already failed an earlier TFR attempt. Now, this patient population has a relatively high probability of around 75% to already experience a TFR failure within the first year. So in this patient population, we hope to see, in the quickest possible way, an initial effect of the treatment of vididencel. So with these two trials, we have set out a strategy to enter CML as a very large and also, of course, from a patient's perspective, high medical need indication.
And we hope, assuming a good initial safety readout from the Phase 1 trial, to start both of these trials this year in 2026.
So with that, I would like to summarize where we currently stand. We have the data from the ADVANCE II trial to support a broader positioning of Vididencel in AML. So we have already engaged in the CADENCE trial, and we will engage this year in the DIVA trial, which will combine Vididencel with Azacitidine and Venetoclax. That, combined with, of course, keeping a close eye on how first-line treatment of AML will evolve, if we will continue to see separate patient populations which are classified as fit and unfit, or whether we will start to see a larger shift where the decision between high-intensity chemotherapy and Venetoclax will become more granular. That is something we keep a close eye on. And those developments, combined with our own data from the trials that we have now set out, will inform us, of course, about the best possible registration trial for Vididencel in AML.
And then we are very excited, of course, to enter CML as a new field again, starting with the VITAL-CML phase one trial, and then in parallel after the initial safety data have been confirmed, the start of the VITAL-TFR2 phase two trial, and then to conclude the ALISON trial. We are very happy with the data we have collected in the trial that confirms safety and feasibility of Vididencel in this indication, including the induction of tumor-directed immune responses that were associated with durable clinical responses. And we do believe that ovarian cancer, due to the nature of the disease—a solid tumor with a very demanding intratumoral environment—will probably need a combination with other drugs to enhance its effectiveness in treating this disease. So we see the ALISON trial currently as a good basis for potential partnering and developing combination therapies in this indication.
With that, I would like to conclude.
So the positive ADVANCE II Phase 2 data support a broad positioning of Vididencel as a post-remission therapy in AML. The strategic direction we implemented with our updated clinical strategy last year was also supported by the data presented at ASH concerning the evolving first-line treatment landscape in AML. So we now have an up-to-date and attractive development strategy in AML, which is basically positioning Vididencel as broadly as possible as a post-remission treatment.
We're very excited to add CML as a new indication, which is a very large indication, but also, of course, with a good clinical rationale to use Vididencel as an active immunotherapy to allow patients to have a better chance of treatment-free remission. And for the ALISON trial data, we are happy that we have them currently at hand as the basis for potential combination therapy and potential collaboration. So with that, we have an exciting outlook for the upcoming year, with multiple clinical milestones anticipated in 2026, and particularly, of course, the first-in-human data in Chronic Myeloid Leukemia, which we expect in the second half of next year.
With that, I would like to open up the session for questions.